Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme

Molecules

卷:24

Zbynek Novy¹  Dominika Flasarova¹  Miroslav Popper¹  Milos Petrik¹  Jana Stepankova¹  Michaela Hola¹ 

[1] Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic;

关键词: PET;    RGD peptides;    biodistribution;    gallium-68;    ¹⁸F-FDG;    ¹⁸F-FLT;    glioblastoma multiforme;   

DOI  :  10.3390/molecules24132496

来源: DOAJ

【 摘 要 】

In this study, we have compared four ⁶⁸Ga-labeled peptides (three Arg-Gly-Asp (RGD) peptides and substance-P) with two ¹⁸F-tracers clinically approved for tumor imaging. We have studied in vitro and in vivo characteristics of selected radiolabeled tracers in a glioblastoma multiforme tumor model. The in vitro part of the study was mainly focused on the evaluation of radiotracers stability under various conditions. We have also determined in vivo stability of studied ⁶⁸Ga-radiotracers by analysis of murine urine collected at various time points after injection. The in vivo behavior of tested ⁶⁸Ga-peptides was evaluated through ex vivo biodistribution studies and PET/CT imaging. The obtained data were compared with clinically used ¹⁸F-tracers. ⁶⁸Ga-RGD peptides showed better imaging properties compared to ¹⁸F-tracers, i.e., higher tumor/background ratios and no accumulation in non-target organs except for excretory organs.

【 授权许可】

Unknown